enGene (ENGN) financial statements
Net income was -$117M.
Free cash flow was -$101M.
The diluted share count rose 7703% over the period (dilution).
Income statement
Fiscal years, from enGene's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Research and development | $15M | $16M | $38M | $94M |
| Selling, general and admin | $4M | $10M | $24M | $29M |
| Operating income | -$19M | -$26M | -$62M | -$123M |
| Interest expense | $1M | $5M | $3M | $3M |
| Pre-tax income | -$24M | -$100M | -$55M | -$117M |
| Income tax | $22,000 | $17,000 | -$19,000 | $0 |
| Net income | -$24M | -$100M | -$55M | -$117M |
| EPS (diluted) | $44.30 | $151.22 | $1.46 | $2.29 |
| Diluted shares | 1M | 1M | 38M | 51M |
Balance sheet
Fiscal years, from enGene's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Cash and short-term investments | $20M | $82M | $238M | $194M |
| Total current assets | $23M | $85M | $247M | $201M |
| Property, plant and equipment | $387,000 | $589,000 | $1M | $2M |
| Total assets | $24M | $87M | $311M | $221M |
| Total current liabilities | $5M | $5M | $15M | $32M |
| Total liabilities | $47M | $14M | $39M | $54M |
| Shareholders' equity | -$77M | $72M | $273M | $168M |
| Net debt | -$20M | -$82M | -$173M | -$50M |
Cash flow
Fiscal years, from enGene's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -$18M | -$25M | -$48M | -$99M |
| Capital spending | $153,000 | $318,000 | $925,000 | $1M |
| Free cash flow | -$18M | -$25M | -$49M | -$101M |
| Stock-based compensation | $116,000 | $3M | $5M | $10M |
| Dividends paid | — | $0 | — | — |
| Net borrowing | $10M | — | $22M | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ENGN.
Open ENGN in InvestinglyQuestions
How much free cash flow does enGene generate?
-$101M in fiscal 2025 (operating cash flow minus capital spending).
From enGene's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.